

May 2019

PRODUCT NEWS



A Smarter Approach to 24/7 Heart Monitoring

Our next-generation **Confirm Rx™** insertable cardiac monitor (ICM), a paperclip-sized implantable device, just launched in the U.S. and Europe. The Confirm Rx ICM device is the only ICM on the market that syncs to a smartphone via Bluetooth® and transmits information to the physician to help identify irregular heartbeats quickly. Read more [here](#).

INNOVATION



Late-Breaking Data for Leaky Tricuspid Heart Valves

People living with difficult-to-treat leaks in their heart's tricuspid valve saw encouraging news from the latest Triluminate study unveiled in Paris. The study evaluated the safety and efficacy of Abbott's minimally invasive tricuspid valve repair system in reducing tricuspid valve leaks and associated symptoms. [Read more here](#).



Abbott Blood Test Helps Predict Future Cardiac Events

Every 40 seconds, someone in the U.S. has a heart attack. A new study finds our High Sensitive Troponin-I blood test could help predict cardiac events in adults with no known heart disease. Researchers suggest doctors could add the test to routine physical assessments in healthy middle-aged and older adults. Read about new data published in the journal *Circulation*.



Partnership Targets Blood Test for Concussions

Abbott announced the next phase of its partnership with the U.S. Department of Defense and researchers from the [Transforming Research and Clinical Knowledge in Traumatic Brain Injury \(TRACK-TBI\)](#) Network. The groups will conduct a clinical trial to evaluate the effectiveness of Abbott's point-of-care blood test technology, which is under development to help clinicians assess brain injuries within minutes, using only a few drops of blood.



Nutritional Breakthrough for the Immune System

Abbott was the first company in the world to include Human Milk Oligosaccharides (HMOs) in infant formula with the introduction of Similac Pro-Advance and Pro-Sensitive, bringing about one of the biggest advances in infant nutrition in the last decade. Read more about this important ingredient in [Bloomberg](#).

STRATEGY SPOTLIGHT



Moody's Upgrades Abbott's Credit Rating a Third Time

With two major acquisitions behind it, Abbott has carefully tended to its balance sheet, and Wall Street debt watchers have taken notice. On May 3, Moody's Investors Service upgraded Abbott's unsecured credit rating for the third time in 15 months. The agency wrote that the upgrade "reflects Moody's expectations that Abbott will maintain its recent track record of strong organic revenue growth and operating margin improvement."



Medtech Insights: Exec Chat

Dr. John Frels, vice president of R&D for Abbott's diagnostics business, caught up with *Medtech Insight* about our approach to leading in innovation, how we've evolved to stay relevant for 130 years and what new products are coming in 2019. [Read more here](#).

For the latest on what's happening at Abbott, visit us at www.abbottinvestor.com or follow us on [Twitter](#) and [LinkedIn](#).

